AOD-9604

The sequence of AOD-9604 corresponds to residues 176–191 of native growth hormone, with a C-terminal amide to enhance stability. It is produced by Fmoc solid-phase peptide synthesis (building each amino acid sequentially on a solid support). Purification by high-performance liquid chromatography yields research-grade material at over 95 percent purity. Final quality control uses mass spectrometry to confirm correct molecular weight and sequence.

AOD-9604 upregulates β₃-adrenergic receptors on adipocytes (fat cells), promoting lipolysis (fat breakdown). It does not significantly alter insulin-like growth factor-1 (IGF-1) or glucose metabolism in human subjects. The action is focused on activating the body’s fat-breakdown pathways without broader hormonal effects. Receptor changes and increased fat mobilization are observed within weeks of daily dosing.

The peptide has been evaluated primarily for weight-management and metabolic-health research. In human studies, participants experienced modest additional fat reduction compared with placebo and showed improved lipid profiles. Insulin sensitivity remained stable throughout treatment. Development beyond early trials ceased due to limited overall efficacy.

Reported adverse events in human trials were generally mild and transient, most commonly headache and injection-site redness. No serious safety issues or clinically meaningful hormonal imbalances were observed during up to 12 weeks of use. Long-term safety data beyond three months are not available. Recommended monitoring includes regular lipid panels and fasting glucose.

AOD-9604 is assembled by Fmoc solid-phase peptide synthesis (a method of sequentially adding amino acids to a growing chain on a resin). After cleavage, it is purified by high-performance liquid chromatography to over 95 percent purity. Mass spectrometry confirms correct sequence and molecular weight. Production follows research-grade peptide compounding standards.

AOD-9604 is classified for research use only and is not approved by the U.S. FDA, EMA, or other major regulatory agencies. It cannot be prescribed or sold as a therapeutic. Laboratories may obtain it under investigational peptide regulations, which vary by region. No clinical or over-the-counter formulations exist.

Clinical studies administered 250–500 µg by subcutaneous injection once daily for up to 12 weeks. No standardized dosing guidelines exist outside approved research protocols. Dosing regimens beyond these parameters lack validation. All use should adhere to institutional review board–approved study designs.

Do follow approved research protocols with ethical oversight.Do monitor lipid profiles and fasting glucose regularly.Don’t combine with full-length growth hormone or insulin outside a trial.Don’t use in pregnancy, lactation, or active malignancy.

Q: When does fat reduction become measurable?A: Reductions were typically detected after 4–6 weeks of daily dosing.Q: Does AOD-9604 affect IGF-1 levels?A: No significant changes in IGF-1 were reported in human studies.Q: Can it be administered orally?A: No; only subcutaneous injection has been evaluated.